S Sciarretta's research while affiliated with Sapienza University of Rome and other places

... Despite that there is much evidence that ANP T2238C is associated with cardiovascular disease risk (5,12,13), a comprehensive synthesis and analysis of the existing data are lacking. Therefore, the present study aimed to fill this gap by systematically collecting and summarizing available data on the association between ANP T2238C and cardiovascular disease risk. ...

... myocardial ischemia), a clinical condition defined as "hypertension emergency". Indeed, uncontrolled hypertension represents by far the most common underlying cause of acute coronary syndrome (ACS) in patients without overt CV diseases in the setting of primary prevention [2]. At the same time, it has been associated to an increased risk of recurrent coronary events in those patients with known history of coronary artery disease (CAD) in the setting of secondary prevention [3]. ...

... It is important to note that the blood pressure can influence the risk of restenosis [33]; a high blood pressure is associated with increased risk of restenosis [34]. Regarding Figure 7 and Table 8, the blood pressure values were within the normal blood pressure values before stent implantation [19]. ...

... In view of the fact that all factors considered for the definition of the metabolic syndrome should be within the high-normal thresholds, great relevance has been devoted to this condition from a preventive point of view [12]. In fact, early identification and prompt correction of these risk factors has been associated with a reduced incidence of cardiovascular events. ...

... These include poor patients' adherence to prescribed medications, insufficient physician-patient communication, clinical inertia, availability of heterogeneous sets of guidelines giving often contradictory recommendations on BP targets as well as on therapeutic indications, and excessive pill burden [13,14]. In particular, a major drive responsible for a substantial proportion of the failure in reaching the recommended BP goals may be linked to the persistently high use of monotherapy in the setting of clinical practice, whereas combination therapy is still largely viewed as a second-choice option for hypertension management [15]. ...

... The goal of assessment and risk stratification is to identify high-risk hypertensive patients who would derive the maximum benefit from treatment compared to low-risk hypertensive whose benefit from antihypertensive treatment may not be favorable in terms of risk-benefit ratio, considering the long-term treatment side effects. [5,6] While the presence of target organ damage is a definite indication for initiating treatment, physicians have been looking for simpler clinical tools to identify high-risk individuals. BP that does not dip down to the normal physiological range during the night has been identified as a reliable indicator of increased cardiovascular complications in the future and is emerging as an independent and powerful marker for high-risk hypertensive patients. ...

... In addition, our research group has previously investigated the contributory role of several candidate genes into the susceptibility to develop IS of this Sardinian cohort. In fact, we demonstrated a direct contributory role to IS occurrence for the following gene variants: atrial natriuretic peptide (C2238T) [51], type 1 angiotensin II receptor (A1166C) [52], Factor VII (-C122T) [53], cholesteryl ester transfer protein Taq1 B1/B2) [54], β2-adrenergic receptor (Gln27Glu) [55], and platelet glycoprotein IIIa (PlA1/A2) [56]. Conversely, we found no evidence of association for the phosphodiesterase-4D (PDE4D) and 5-lipoxygenase activating protein (ALOX5AP) gene variants with the risk of IS [57]. ...